Literature DB >> 24053272

Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections.

James Soothill1.   

Abstract

Phage therapy for Pseudomonas aeruginosa infections has been used for more than 50 years. Controlled investigation into its use dates from the early 1990s when positive laboratory studies of local and systemic infection were followed by clinical studies: symptomatic improvement and phage multiplication were seen in a pet dog with otitis and a human with an infected burn. Antibiotic resistance has renewed interest in this approach. There have been recent positive reports in the treatment of experimental animal infection including systemic and respiratory infections. Phages have shown promise against experimental biofilms. Two small recent clinical trials in otitis, of dogs and of human patients have provided some encouraging results. Phage has potential in the treatment of antibiotic resistant infection by P. aeruginosa. Hence, full scale clinical trials are needed.

Entities:  

Mesh:

Year:  2013        PMID: 24053272     DOI: 10.1586/14787210.2013.826990

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  14 in total

1.  Experimental phage therapy of burn wound infection: difficult first steps.

Authors:  Thomas Rose; Gilbert Verbeken; Daniel De Vos; Maya Merabishvili; Mario Vaneechoutte; Rob Lavigne; Serge Jennes; Martin Zizi; Jean-Paul Pirnay
Journal:  Int J Burns Trauma       Date:  2014-10-26

2.  Current Research Approaches to Target Biofilm Infections.

Authors:  Erik van Tilburg Bernardes; Shawn Lewenza; Shauna Reckseidler-Zenteno
Journal:  Postdoc J       Date:  2015-06

Review 3.  Targeting Microbial Bio-film: an Update on MDR Gram-Negative Bio-film Producers Causing Catheter-Associated Urinary Tract Infections.

Authors:  Susmita Chakrabarty; Monali P Mishra; Dipankar Bhattacharyay
Journal:  Appl Biochem Biotechnol       Date:  2022-03-05       Impact factor: 2.926

Review 4.  Call for a dedicated European legal framework for bacteriophage therapy.

Authors:  Gilbert Verbeken; Jean-Paul Pirnay; Rob Lavigne; Serge Jennes; Daniel De Vos; Minne Casteels; Isabelle Huys
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-02-06       Impact factor: 4.291

Review 5.  Strategies for combating bacterial biofilm infections.

Authors:  Hong Wu; Claus Moser; Heng-Zhuang Wang; Niels Høiby; Zhi-Jun Song
Journal:  Int J Oral Sci       Date:  2015-03-23       Impact factor: 6.344

6.  Characterization of the first double-stranded RNA bacteriophage infecting Pseudomonas aeruginosa.

Authors:  Yuhui Yang; Shuguang Lu; Wei Shen; Xia Zhao; Mengyu Shen; Yinling Tan; Gang Li; Ming Li; Jing Wang; Fuquan Hu; Shuai Le
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

Review 7.  Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.

Authors:  Lucy L Furfaro; Matthew S Payne; Barbara J Chang
Journal:  Front Cell Infect Microbiol       Date:  2018-10-23       Impact factor: 5.293

8.  Phage-Bacterial Dynamics with Spatial Structure: Self Organization around Phage Sinks Can Promote Increased Cell Densities.

Authors:  James J Bull; Kelly A Christensen; Carly Scott; Benjamin R Jack; Cameron J Crandall; Stephen M Krone
Journal:  Antibiotics (Basel)       Date:  2018-01-29

9.  Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II.

Authors:  Wilbert Sybesma; Christine Rohde; Pavol Bardy; Jean-Paul Pirnay; Ian Cooper; Jonathan Caplin; Nina Chanishvili; Aidan Coffey; Daniel De Vos; Amber Hartman Scholz; Shawna McCallin; Hilke Marie Püschner; Roman Pantucek; Rustam Aminov; Jiří Doškař; D İpek Kurtbӧke
Journal:  Antibiotics (Basel)       Date:  2018-04-23

Review 10.  Antimicrobial Photodynamic Therapy to Control Clinically Relevant Biofilm Infections.

Authors:  Xiaoqing Hu; Ying-Ying Huang; Yuguang Wang; Xiaoyuan Wang; Michael R Hamblin
Journal:  Front Microbiol       Date:  2018-06-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.